Masimo Announces Iris™ Gateway at HIMSS16
Integrated Medical Device Data Management Solution Designed to Fill the Gaps in Electronic Medical Records
March 01, 2016 08:03 AM Eastern Standard Time
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced the debut of Iris™ Gateway, a server-based software solution for integrating medical device data, at the HIMSS (Healthcare Information and Management Systems Society) 2016 Annual Conference and Exhibition in Las Vegas.
"Iris Gateway is an important part of Masimo's goal of bridging medical device data silos"
Data generated from medical devices remain captive within each device, and may not be captured in the patients' electronic medical records (EMR). Iris Gateway can provide a timely and cost-effective solution by connecting to existing medical devices and performing the required translations to move the data from the devices into EMRs. Iris Gateway can be deployed on a remote server farm or as a server appliance in the hospital.
The Iris ports on the Root® patient monitor allow other medical devices (such as infusion pumps, ventilators, patient monitors, and "smart" beds) to connect to Iris Gateway via Root. Data from these connected devices can be associated with the patient and entered into the patient's EMR, via Iris Gateway. Root with noninvasive blood pressure and temperature measurements, deployed at the bedside or on a roll stand, can chart these parameters at the point of care while also copying the data into an EMR.
"Iris Gateway is an important part of Masimo's goal of bridging medical device data silos," said Joe Kiani, Founder and CEO of Masimo. "It can be used to connect isolated devices to hospital EMR systems in high-acuity settings like the OR and the ICU or in low-acuity settings like medical-surgical units. When data from different medical devices is more readily available in the patient's electronic medical record, they may provide a clearer and more complete picture of the patient. At Masimo, we are dedicated to providing clinicians with vital information when they need it most."
For more information on Masimo and its products, go to www.masimo.com.
@MasimoInnovates | #Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. The benefits of Masimo SET® have been proven in more than 100 independent and objective studies and it is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive open architecture patient monitoring and connectivity platform designed to speed the pace of innovation and reduce the cost of care. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo's Iris™ Gateway. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Iris™ Gateway, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Irene Paigah, 858-859-7001